归还前次用于临时补充流动资金的募集资金 暨使用部分闲置募集资金临时补充流动资金的核查意见 根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管规则》《上海 证券交易所科创板上市公司自律监管指引第1号——规范运作》《上海证券交易所科创 板股票上市规则》《科创板上市公司持续监管办法（试行）》等有关规定，作为长春 百克生物科技股份公司（以下简称"百克生物"或"公司"）首次公开发行股票并上市的 保荐机构，中信证券股份有限公司（以下简称"中信证券"）对百克生物归还前次用于 临时补充流动资金的募集资金暨使用部分闲置募集资金临时补充流动资金的情况进行 了核查，具体如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于同意长春百克生物科技股份公司首次公开发行 股票注册的批复》（证监许可[2021]1594号）的同意，公司采用向社会公开发行方式 发行人民币普通股（A股）41,284,070股，发行价格为每股36.35元，募集资金总额 1,500,675,944.50元，扣除承销费、保荐费、审计费、律师费、信息披露等发行费用 104,881,526.35元后，实际募集资金净额为1,395,794,418.15元。上述 ...

证券代码：688276 证券简称：百克生物 公告编号：2025-025 长春百克生物科技股份公司 关于归还前次用于临时补充流动资金的募集资金 暨使用部分闲置募集资金临时补充流动资金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2025年7月25日，长春百克生物科技股份公司（以下简称"公司"或 "百克生物"）已将前次用于临时补充流动资金的募集资金10,000万元归还至 募集资金专用账户，并及时将募集资金归还情况通知保荐机构和保荐代表人。 公司拟使用不超过人民币10,000万元的闲置募集资金临时补充流动资金， 使用期限自公司董事会决议通过之日起不超过12个月。 上述资金到位情况经大信会计师事务所（特殊普通合伙）验证，并出具了大信 验字[2021]第7-00002号《长春百克生物科技股份公司验资报告》。 公司对募集资金采取了专户存储制度，前述募集资金到账后，已存放于募 集资金专户，并与保荐机构、募集资金专户监管银行签署《募集资金专户存储 三方监管协议》（以下简称"监管协议"）。监管协议与证券交易所监管协 ...

Group 1 - The core viewpoint of the news highlights a significant rise in virus prevention stocks, particularly in response to the reported cases of Chikungunya fever in Foshan, Guangdong Province [1][2][3] - Notable stock performances include Zhifei Biological, which increased by 16.86%, and Watson Bio, which rose by 13.39%, among others [2] - The total market capitalization of Zhifei Biological is reported at 57.7 billion, while Watson Bio stands at 21 billion [2] Group 2 - As of July 22, Foshan has reported a total of 3,195 confirmed cases of Chikungunya fever, primarily concentrated in the Shunde District [2] - The World Health Organization has issued a warning regarding mosquito-borne diseases, urging countries to prepare for potential outbreaks [3]

Group 1 - The A-share biopharmaceutical sector experienced a significant afternoon rally, with notable increases in stock prices [1] - Zhifei Biological surged over 14%, while Watson Bio rose more than 12% [1] - Other companies such as Kangtai Biological, Sanyuan Gene, Bohui Innovation, Baike Biological, and Zhixiang Jintai also saw gains [1]

Core Viewpoint - The article discusses the significant developments in the field of shingles vaccines in China, highlighting the price reduction initiatives and the emergence of domestic vaccine production, particularly by Changchun Baike Biotechnology Co., Ltd. [5][6] Group 1: Vaccine Market Dynamics - The shingles vaccine market in China is experiencing a price reduction trend, driven by the "Healthy China" strategy, which aims to enhance public health through affordable vaccination programs [5]. - There are currently two approved shingles vaccines in China: one imported and one domestically produced by a company based in Changchun, Jilin [5][6]. Group 2: Company Innovations and Developments - Changchun Baike Biotechnology has launched the first domestically developed live attenuated shingles vaccine for individuals aged 40 and above, breaking the monopoly of imported vaccines in the market [6]. - The parent company, Changchun High-tech Industry (Group) Co., Ltd., has shifted its focus towards innovation in the biopharmaceutical sector, investing over 8.5 billion yuan in research and development [6][8]. Group 3: Regional Industry Growth - The biopharmaceutical industry in Changchun is supported by a robust infrastructure and educational resources, including institutions like the Chinese Academy of Sciences and several key universities [8]. - The biopharmaceutical and life health industry in Changchun is projected to achieve a production value of 110 billion yuan in 2024, reflecting a year-on-year growth of 12.5% [8][11]. Group 4: Future Prospects - The "Yongchun Biopharmaceutical City" is under construction, with 33 projects and a total investment of 15.2 billion yuan, expected to generate a production value of 60 billion yuan by 2035 [11]. - The local government has introduced a three-year action plan to further develop the biopharmaceutical and life health industry as a new growth engine for the city's economy [11][13].

1、长春百克生物科技股份公司（以下简称"公司"）近日收到国家药品监督 管理局下发的流感病毒裂解疫苗（BK-01 佐剂）的《药物临床试验批准通知书》。 证券代码：688276 证券简称：百克生物 公告编号：2025-024 长春百克生物科技股份公司 关于自愿披露流感病毒裂解疫苗（BK-01 佐剂） 临床试验申请获得批准的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2、本次获批临床试验的流感病毒裂解疫苗（BK-01 佐剂）后续临床试验的开 展具有一定的不确定性，能否最终实现商业目的也存在一定的不确定性。敬请广大 投资者谨慎决策，注意防范投资风险。 现将相关情况公告如下： 一、《药物临床试验批准通知书》的主要信息 受理号：CXSL2500239 通知书编号：2025LP01603 药品名称：流感病毒裂解疫苗（BK-01 佐剂） 结论：同意开展预防疫苗相关型别流感病毒引起的流行性感冒的临床试验。 批准日期：2025 年 6 月 19 日 二、流感病毒裂解疫苗（BK-01 佐剂）的简介 流感是由流感病毒引起 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for a clinical trial of its influenza virus split vaccine (BK-01 adjuvant), targeting individuals aged 60 and above to prevent influenza caused by the virus [1] Group 1 - The vaccine is designed specifically for the elderly population, which is at higher risk for influenza complications [1] - The vaccine utilizes a split virus technology route combined with a self-developed adjuvant to enhance immunogenicity [1] - Successful development of this vaccine will enrich the company's influenza vaccine research pipeline and provide new vaccination options for the elderly [1]

证券代码：688276 证券简称：百克生物 公告编号：2025-023 长春百克生物科技股份公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/17 | 2025/6/18 | 2025/6/18 | 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 13 日的2024年年度股东会审议通过。 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 1. 发放年度：2024年年度 2. 分派对象： 3. 分配方案： 本次利润分配以方案实施前的公司总股本413,657,598股为基数，每股派发现 金红利0.169元（含税），共计派发现金红利69,908,134.06元（含税）。 三、 相关日期 1 是否涉及差异化分红送转：否 每 ...

Core Viewpoint - Changchun Baike Biotechnology Co., Ltd. has announced a cash dividend distribution of 0.169 CNY per share, totaling approximately 69.91 million CNY, approved at the 2024 annual shareholders' meeting on May 13, 2025 [1][2]. Dividend Distribution Plan - The total share capital before the distribution is 413,657,598 shares, with a cash dividend of 0.169 CNY per share, amounting to a total distribution of 69,908,134.06 CNY (including tax) [1]. - The cash dividend will be distributed to all shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, after the market closes on the registration date [1]. Relevant Dates - The key dates for the dividend distribution are as follows: - Registration Date - Ex-Dividend Date - Cash Dividend Payment Date [1]. Taxation Policies - For individual shareholders holding unrestricted circulating shares, dividends are subject to different tax treatments based on the holding period: - Over 1 year: Tax-exempt on dividend income, actual cash dividend per share is 0.169 CNY [2]. - 1 year or less: No withholding tax at the time of distribution; tax will be calculated upon sale of shares [2]. - For shares held less than 1 month, the effective tax burden is 20% [2]. Special Cases for Restricted Shares - For shareholders holding restricted shares, dividends received after the lifting of restrictions will be taxed similarly to unrestricted shares, while dividends received before the lifting will be taxed at a reduced rate [3]. - Non-resident enterprises holding restricted shares will be taxed at a rate of 10%, with a net dividend of 0.1521 CNY per share [4]. QFII and Hong Kong Investors - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax on dividends, resulting in a net dividend of 0.1521 CNY per share [4]. - Investors from Hong Kong holding shares through the Shanghai-Hong Kong Stock Connect will also face a 10% withholding tax, with the same net dividend amount [5]. Contact Information - For inquiries regarding the dividend distribution, shareholders can contact the Board Office at 0431-81871518 [6].

一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 13 日的2024年年度股东会审议通过。 证券代码：688276 证券简称：百克生物 公告编号：2025-023 长春百克生物科技股份公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 股权登记日 | 除权（息）日 | 现金红利发放日 | | --- | --- | --- | | 2025/6/17 | 2025/6/18 | 2025/6/18 | 二、 分配方案 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任 公司上海分公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东。 1 是否涉及差异化分红送转：否 每股分配比例 每股现金红利0.169元 相关日期 1. 发放年度：2024年年度 2. 分派对象： 3. 分配方案： 本次利润分配以方案实施前的公司总股本413,657,598股为基数，每股派发现 金红利0.169元（含税），共计派发现金红利69,9 ...